Search results
This chapter provides an overview of inhaled therapy for the management of asthma and COPD. The operation principles, merits and limitations of different delivery technologies are examined. Looking ahead, the challenges of delivering novel therapeutics such as biologics through the pulmonary route are also discussed.
Studies investigating RNA therapeutics in pulmonary diseases have rapidly expanded and drug administration by inhalation allows the direct delivery of RNA therapeutics to the target site of action while minimizing systemic exposure.
- Michael Y.T. Chow, Michael Y.T. Chow, Yingshan Qiu, Jenny K.W. Lam
- 2020
Michael Y.T. Chow's 33 research works with 1,650 citations and 21,161 reads, including: Delivery technology of inhaled therapy for asthma and COPD
The clustered regulatory interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (CRISPR/Cas9) system has significant therapeutic potentials for lung congenital diseases such as cystic fibrosis, as well as other pulmonary disorders like lung cancer and obstructive diseases.
- Michael Y.T. Chow, Rachel Yoon Kyung Chang, Hak-Kim Chan
- 2021
Michael Y.T. Chow,1,2,3 Yingshan Qiu,1,3 and Jenny K.W. Lam1,* RNA-based medicine is receiving growing attention for its diverse roles and potential therapeutic capacity. The largest obstacle in its clinical translation re-mains identifying a safe and effective delivery system. Studies investigating
Michael Chow is A serial entrepreneur and venture capitalist at the intersection of media, entertainment and technology. He has co-founded several entities, including MNM Creative, a financing vehicle for multi-cultural and diversity driven content.
People also ask
Who is Michael Chow?
How many locations does Mr Chow have?
What is Mr Chow's Destiny?
Oct 17, 2023 · In the HBO-backed doc, the restaurateur and artist talks about what drove him to build his eponymous global restaurant empire, as well as his personal losses: “All kinds of unspeakable tragedies ...
